Sobi has completed SEK 3 billion senior bond issue

The bond issue generated strong investor interest and was oversubscribed. The bond issue generated strong investor interest and was oversubscribed. The bonds will be listed on Nasdaq Stockholm. Nordea and SEB acted as lead managers on the transaction. Mannheimer Swartling Advokatbyrå acted as legal adviser to Sobi. Sobi Sobi ®is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to...

The bond issue generated strong investor interest and was oversubscribed.

The bonds will be listed on Nasdaq Stockholm.

Nordea and SEB acted as lead managers on the transaction. Mannheimer Swartling Advokatbyrå acted as legal adviser to Sobi.

Sobi

Sobi^® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-has-completed-sek-3-billion-senior-bond-issue,c3975776

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/sobi-has-completed-sek-3-billion-senior-bond-issue-302139588.html